11.04.2011 • NewsDaniel VasellaNovartisAlcon

Novartis Eyes Debts, Possible Smaller Buys

Swiss drugmaker Novartis will focus on its debts before undertaking any big purchases following its acquisition of eyecare group Alcon, Novartis's chairman was quoted as saying on Saturday.

The Basel-based firm spent much of last year trying to clinch 100% ownership of Alcon and has finally sealed its $50.9 billion buy by paying Alcon's minority shareholders an extra $463 million in cash.

"Now it's about cutting back on the debt burden somewhat before we can undertake new big buys," Chairman Daniel Vasella told Swiss newspaper Blick. "But smaller bolt-ons are surely still possible in the near future."

Vasella, who previously served as the firm's chief executive, also said the Alcon buy was expected to yield synergies of more than $300 million in the next three years.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.